Coherus Names Paul Reider Chief Commercial Officer
February 15 2022 - 4:30PM
Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”,
“Coherus”) today announced Paul Reider has been named Chief
Commercial Officer. Mr. Reider previously held the position of
Executive Vice President of Commercial Operations and Market
Access.
“Paul has a demonstrated record of success in biopharmaceutical
sales and marketing, having led multiple successful commercial
launches and managed blockbuster oncology brands. I am excited to
name him Chief Commercial Officer. His broad experience launching
specialty brands, deep relationships with customers and payers, and
leadership skills will prove invaluable to Coherus as we prepare to
launch as many as five new products over the next 18 months,” said
Denny Lanfear, CEO of Coherus.
Mr. Reider has 30 years of biotechnology industry sales and
marketing experience across oncology, rheumatology, endocrinology
and rare disease therapeutic areas. Prior to joining Coherus in
2021, he served as Vice President of Sales and Strategic Accounts
for Puma Biotechnology. He led the establishment of a new
U.S.-based oncology commercial team at Ipsen Biopharmaceuticals and
subsequently served as the General Manager of Ipsen Canada. From
1996 to 2013, he held marketing and executive leadership roles at
Amgen including marketing lead for the U.S. launch of Neulasta®,
which grew to become a $4 billion product in the U.S.; Brand
Director of the Filgrastim Franchise; Executive Director of
Corporate Accounts; commercial leader for the establishment of
Amgen affiliates in Mexico and Brazil; and founding commercial
leader of the Bone Health Business Unit which launched Prolia®, now
a $3.2 billion global brand.
Mr. Reider earned a Bachelor of Science degree in Business
Administration and an M.B.A. from Bowling Green State
University.
"I am honored to be named Chief Commercial Officer at this
pivotal time for Coherus as we become a multi-product company and
execute on our plans to build a leading immuno-oncology franchise,”
said Mr. Reider.
About Coherus BioSciencesCoherus is a
commercial stage biopharmaceutical company building a leading
immuno-oncology franchise funded with cash generated by its
portfolio of FDA-approved products. In 2021, Coherus in-licensed
toripalimab, an anti-PD-1 antibody, in the United
States and Canada. A biologics license application for
toripalimab for the treatment of metastatic or recurrent
nasopharyngeal carcinoma is currently under priority review by the
FDA, with a target action date of April 2022. Toripalimab is
also being evaluated in pivotal clinical trials for the treatment
of cancers of the lung, breast, liver, skin, kidney, stomach,
esophagus, and bladder.
Coherus markets UDENYCA® (pegfilgrastim-cbqv), a biosimilar of
Neulasta® in the United States, and expects to launch the
FDA-approved Humira® biosimilar YUSIMRY™ (adalimumab-aqvh)
in the United States in 2023. The FDA is currently
reviewing the biologics license application for CHS-201, a
biosimilar of Lucentis® (ranibizumab), with a target action date
of August 2022. Coherus is also developing CHS-305, a
biosimilar of Avastin® (bevacizumab).
UDENYCA® and YUSIMRY™ are trademarks of Coherus BioSciences,
Inc.Prolia® and Neulasta® are registered trademarks of AmGen
Inc.Avastin® and Lucentis® are registered trademarks of Genentech,
Inc.Humira® is a registered trademark of AbbVie Inc.
Forward-Looking StatementsExcept for the
historical information contained herein, the matters set forth in
this press release are forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995, including, but not limited to,
statements regarding Coherus’ ability to build its immuno-oncology
franchise to achieve a leading market position; Coherus’ ability to
generate cash; Coherus’ investment plans; and Coherus’ expectations
regarding its ability to launch products over the near term.
Such forward-looking statements involve substantial risks and
uncertainties that could cause Coherus’ actual results, performance
or achievements to differ significantly from any future results,
performance or achievements expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others, the risks and uncertainties inherent in the clinical
drug development process; risks relating to the COVID-19 pandemic;
risks related to our existing and potential collaboration partners;
risks of the drug development position of Coherus’ competitors; the
risks and uncertainties of the regulatory approval process,
including the speed of regulatory review and the timing of Coherus’
regulatory filings; the risk of FDA review issues; the risk of
Coherus’ execution of its change in strategy from a focus on
biosimilars to a strategy using cash from biosimilars to fund an
immuno-oncology franchise; the risk that Coherus is unable to
complete commercial transactions and other matters that could
affect the availability or commercial potential of Coherus’ drug
candidates; and the risks and uncertainties of possible litigation.
All forward-looking statements contained in this press release
speak only as of the date of this press release. Coherus undertakes
no obligation to update or revise any forward-looking statements.
For a further description of the significant risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to Coherus’ business in general, see Coherus’ Annual
Report on Form 10-K for the year ended December 31, 2020,
filed with the Securities and Exchange
Commission on February 25, 2021, its subsequent Quarterly
Reports on Form 10-Q, including the sections therein captioned
“Risk Factors” and in other documents we file with
the Securities and Exchange Commission.
Contact:McDavid StilwellCoherus BioSciences,
Inc.IR@coherus.com
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Apr 2023 to Apr 2024